Glaucoma medical therapy: Difference between revisions
| Line 17: | Line 17: | ||
The possible neuroprotective effects of various topical and systemic medications are also being investigated. | The possible neuroprotective effects of various topical and systemic medications are also being investigated. | ||
====Commonly used medications==== | |||
* [[Prostaglandin analogs]] like [[latanoprost]] (Xalatan), [[bimatoprost]] (Lumigan) and [[travoprost]] (Travatan) increase uveoscleral outflow of aqueous humor. | |||
* Topical [[beta-adrenergic receptor antagonists]] such as [[timolol]], levobunolol (Betagan), and [[betaxolol]] decrease aqueous humor production by the ciliary body. | |||
* [[Alpha2-adrenergic agonist]]s such as [[brimonidine]] (Alphagan) work by a dual mechanism, decreasing aqueous production and increasing uveo-scleral outflow. | |||
* Less-selective [[sympathomimetic]]s like [[epinephrine]] and [[dipivefrin]] (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a beta2-agonist action. A two percent epinephine solution may be used topically to reduce IOP in open-angle glaucoma by reducing the production of aqueous humor by vasoconstriction of the ciliary body blood vessels. | |||
* [[Miotic agents]] ([[parasympathomimetic]]s) like [[pilocarpine]] work by contraction of the ciliary muscle, tightening the [[trabecular meshwork]] and allowing increased outflow of the aqueous humour. | |||
* [[Carbonic anhydrase inhibitors]] like [[dorzolamide]] (Trusopt), [[brinzolamide]](Azopt), [[acetazolamide]] (Diamox) lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body. | |||
==References== | ==References== | ||
Revision as of 05:04, 23 August 2012
|
Glaucoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glaucoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Glaucoma medical therapy |
|
Risk calculators and risk factors for Glaucoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]
Overview
Although intraocular pressure is only one major risk factors of glaucoma, lowering it via pharmaceuticals or surgery is currently the mainstay of glaucoma treatment. In Europe, Japan, and Canada laser treatment is often the first line of therapy. In the U.S., adoption of early laser has lagged, even though prospective, multi-centered, peer-reviewed studies, since the early '90s, have shown laser to be at least as effective as topical medications in controlling intraocular pressure and preserving visual field. Some studies suggest that acupuncture can be very helpful in the treatment of Glaucoma. [1] [2]
Medical Therapy
Drugs
Intraocular pressure can be lowered with medication, usually eye drops. There are several different classes of medications to treat glaucoma with several different medications in each class.
Each of these medicines may have local and systemic side effects. Adherence to medication protocol can be confusing and expensive; if side effects occur, the patient must be willing either to tolerate these, or to communicate with the treating physician to improve the drug regimen.
Poor compliance with medications and follow-up visits is a major reason for vision loss in glaucoma patients. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms. Ophthalmologists have debated whether glaucoma eye drops should initially be started in both eyes or in just one eye (a binocular or monocular trial), but it appears either strategy is reasonable when properly interpreted. [3]
The possible neuroprotective effects of various topical and systemic medications are also being investigated.
Commonly used medications
- Prostaglandin analogs like latanoprost (Xalatan), bimatoprost (Lumigan) and travoprost (Travatan) increase uveoscleral outflow of aqueous humor.
- Topical beta-adrenergic receptor antagonists such as timolol, levobunolol (Betagan), and betaxolol decrease aqueous humor production by the ciliary body.
- Alpha2-adrenergic agonists such as brimonidine (Alphagan) work by a dual mechanism, decreasing aqueous production and increasing uveo-scleral outflow.
- Less-selective sympathomimetics like epinephrine and dipivefrin (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a beta2-agonist action. A two percent epinephine solution may be used topically to reduce IOP in open-angle glaucoma by reducing the production of aqueous humor by vasoconstriction of the ciliary body blood vessels.
- Miotic agents (parasympathomimetics) like pilocarpine work by contraction of the ciliary muscle, tightening the trabecular meshwork and allowing increased outflow of the aqueous humour.
- Carbonic anhydrase inhibitors like dorzolamide (Trusopt), brinzolamide(Azopt), acetazolamide (Diamox) lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body.
References
- ↑ Clinical application of acupuncture in ophthalmology. Dabov S; Goutoranov G; Ivanova R; Petkova N Acupunct Electrother Res 1985, 10 (1-2) p79-93
- ↑ New Peer Reviewed Study treating open angle glaucoma with acupuncture, [1]
- ↑ Interpretation of uniocular and binocular trials of glaucoma medications: an observational case series,[2]